Nachrichten zur Hims & Hers Health Aktie

Hims & Hers executives struck a confident tone about the companys growth prospects on Monday as it launches new specialties…

Hims & Hers and Amwell are taking different paths in telehealth, but which stock offers the stronger opportunity today? Lets…

Hims & Hers Health is facing existential risk as regulatory uncertainty and margin erosion undermine its growth narrative. Click here…

New York (www.aktiencheck.de) - Hims & Hers-Aktienanalyse von Morgan Stanley:Der Analyst von Morgan Stanley, Craig Hettenbach, stuft die Aktie von…

Frankfurt (www.aktiencheck.de) - Hims & Hers-Aktienanalyse von XTB:Jens Klatt, Marktanalyst bei XTB, nimmt die Aktie von Hims & Hers (ISIN:…

Novo Nordisk filed a lawsuit against Hims & Hers Health (NYSE:HIMS) over alleged patent infringement tied to compounded weight loss…

Hims & Hers Health, Inc. (($HIMS)) has held its Q4 earnings call. Read on for the main highlights of the…

Hims & Hers and Amwell are taking different paths in telehealth, but which stock offers the stronger opportunity today? Lets…

Hims & Hers Health remains ultra Bullish despite a near 80% drawdown from 52-week highs, with growth initiatives firmly on…

Hims & Hers Health, Inc., faces GLP-1 headwinds, volatility, and regulatory risk but has strong revenue growth and global upside.…

Hims & Hers Health (NYSE:HIMS) launched a compounded GLP-1 weight-loss medication and withdrew it shortly after following FDA scrutiny.Novo Nordisk…

After reporting earnings yesterday, shares of Hims & Hers Health have fallen not because of fundamentals but rather guidance.…

Hims & Hers Healths revenue grew 59% to $2.35B in 2025, while adjusted EBITDA surged nearly 80% to $318M. Click…

Hims & Hers stock drops after Q4 revenue miss. Outlook trails estimates despite profit beat and strong subscriber growth.…

The S&P 500 was on track for double-digit earnings growth, with more than half of companies having reported Q4 results…

These are the stocks posting the largest moves in early trading.…

Hims & Hers Health (NYSE: HIMS) delivered a beat on both earnings and profitability in Q4 2025, though a soft…

Hims & Hers Health (NYSE: HIMS) delivered a beat on both earnings and profitability in Q4 2025, though a soft…

Hims & Hers Health delivered strong FY25 results with 59% revenue growth to $2.35B and 13% subscriber growth, but faces…

Hims & Hers shares sink after the online health platform issues underwhelming guidance for the current quarter.…

Der US-Telemedizin-Anbieter Hims & Hers hat am Montagabend zwar ein solides Umsatzwachstum für das vierte Quartal 2025 vermeldet. Doch ein…

?? Home Depot (HD): The home-improvement retailers quarterly results topped expectations, despite profit falling. The company said it i…

Hims & Hers (HIMS) faces an SEC investigation over compounded semaglutide disclosures as Q4 earnings beat.…

Hims & Hers Health (NYSE:HIMS) executives used the company’s fourth-quarter and full-year 2025 earnings call to emphasize expanding scale, broader…

In earnings call, Hims & Hers CEO Andrew Dudum addressed the increased scrutiny on compounded GLP-1s and its impact on…

What Is Moving Hims & Hers Health (HIMS) Now? Hims & Hers Health (HIMS) has been drawing attention after a…